Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. China
  4. Shanghai Stock Exchange
  5. Jiangsu Hengrui Medicine Co., Ltd.
  6. News
  7. Summary
    600276   CNE0000014W7

JIANGSU HENGRUI MEDICINE CO., LTD.

(600276)
  Report
End-of-day quote Shanghai Stock Exchange  -  2022-09-22
32.93 CNY   +0.89%
08/22Nomura Adjusts Jiangsu Hengrui Pharmaceuticals' Price Target to 34.13 Yuan From 31.71 Yuan, Keeps at Neutral
MT
08/19Jiangsu Hengrui Medicine Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022
CI
08/07Baidu bags China's first fully driverless robotaxi licenses
RE
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Market Chatter: Jiangsu Hengrui Medicine to Invest $20 Million in Drug Research Company Under Oncology Deal

02/10/2021 | 12:47am EDT


© MT Newswires 2021
All news about JIANGSU HENGRUI MEDICINE CO., LTD.
08/22Nomura Adjusts Jiangsu Hengrui Pharmaceuticals' Price Target to 34.13 Yuan From 31.71 Y..
MT
08/19Jiangsu Hengrui Medicine Co., Ltd. Reports Earnings Results for the Half Year Ended Jun..
CI
08/07Baidu bags China's first fully driverless robotaxi licenses
RE
08/07Baidu Gets Approval for Autonomous Ride-Hailing Services in Two Chinese Cities
DJ
07/05JIANGSU HENGRUI MEDICINE CO., LTD. : Ex-dividend day for final dividend
FA
07/02Tranche Update on Jiangsu Hengrui Medicine Co., Ltd.'s Equity Buyback Plan announced on..
CI
05/11China’s Pharma Firms Post 67% Jump in Profit in 2021
MT
04/25Nomura Adjusts Jiangsu Hengrui Pharmaceuticals' Price Target to 31.71 Yuan From 55.66 Y..
MT
04/22Jiangsu Hengrui Medicine Co., Ltd. Reports Earnings Results for the First Quarter Ended..
CI
03/13Jiangsu Hengrui Medicine Co., Ltd. announces an Equity Buyback for CNY 1,200 million wo..
CI
More news
Analyst Recommendations on JIANGSU HENGRUI MEDICINE CO., LTD.
More recommendations
Financials
Sales 2022 23 233 M 3 260 M 3 260 M
Net income 2022 4 319 M 606 M 606 M
Net cash 2022 17 229 M 2 417 M 2 417 M
P/E ratio 2022 48,6x
Yield 2022 0,42%
Capitalization 210 B 29 466 M 29 466 M
EV / Sales 2022 8,30x
EV / Sales 2023 6,82x
Nbr of Employees 24 491
Free-Float 48,4%
Chart JIANGSU HENGRUI MEDICINE CO., LTD.
Duration : Period :
Jiangsu Hengrui Medicine Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JIANGSU HENGRUI MEDICINE CO., LTD.
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 20
Last Close Price 32,93 CNY
Average target price 51,36 CNY
Spread / Average Target 56,0%
EPS Revisions
Managers and Directors
Wei Dong Chairman-Supervisory Board
Piao Yang Sun Chairman
Xiao-Jing Zhang Chief Medical Officer
Yu Xu Compliance Manager
Shuang Xue Independent Director
Sector and Competitors
1st jan.Capi. (M$)
JIANGSU HENGRUI MEDICINE CO., LTD.-35.06%29 466
JOHNSON & JOHNSON-2.54%438 337
ELI LILLY AND COMPANY12.54%295 941
ROCHE HOLDING AG-18.41%259 291
ABBVIE INC.5.66%252 944
PFIZER, INC.-25.35%247 392